FT
MYGN icon

Fiduciary Trust’s Myriad Genetics MYGN Stock Holding History

Fiduciary Trust’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,438
Closed -$250K – 460
2018
Q3 		$250K Buy
+5,438
New +$242K 0.01% 426
2017
Q3 		– Sell
-4,365
Closed -$113K – 492
2017
Q2 		$113K Buy
+4,365
New +$92.7K ﹤0.01% 515

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fiduciary Trust's MYGN Position: Q4 2018 in Review

Fiduciary Trust sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 5,438 shares — an estimated $250K sold.

Fiduciary Trust first reported a position in MYGN in Q2 2017 and held it in 2 quarters. The position peaked at $250K in Q3 2018. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

  • Fiduciary Trust reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
  • Fiduciary Trust sold 5,438 Myriad Genetics shares in Q4 2018, an estimated $250K.
  • Fiduciary Trust first reported a position in Myriad Genetics in Q2 2017 and held it in 2 quarters.
  • Fiduciary Trust's Myriad Genetics position peaked at $250K in Q3 2018.
  • 264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on Fiduciary Trust's 13F filing for Q4 2018, filed 29 Jan 2019.